MYEOV

Across TCGA pan-cancer cohorts, MYEOV Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MYEOV data layer compared with 22 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MYEOV Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYEOV expression acts as an unfavorable survival marker.

HNSC, SKCM, and CESC are the cancer types where MYEOV Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.102	0.768	<.001	24	view →
SKCM	OS	Median	All	0.216	0.781	.001	15	view →
CESC	DFS	Median	II,III,IV	0.193	0.705	.045	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MYEOV–HNSC (OS)

Open the HNSC breakdown →